Uncategorized
Sarilumab improves vitreous haze, reduces steroid use in noninfectious uveitis
CHICAGO — Patients with posterior segment noninfectious uveitis treated with sarilumab in a multiple-dose, randomized study saw more reductions in vitreous haze and steroid dosing than patients who received placebo, according to a presenter here. “Vitreous haze, visual acuity and central thickness all improved in patients treated with sarilumab for 16 weeks and maintained through 52 weeks,” Quan Dong Nguyen, MD, said at the American Academy of Ophthalmology meeting.